Source link : https://www.newshealth.biz/health-news/tirzepatide-tops-semaglutide-for-weight-loss-in-head-to-head-trial-eli-lilly-says/
Adults on the obesity medication tirzepatide (Zepbound) lost more weight on average than those on semaglutide (Wegovy) in a head-to-head trial of the two injectables, Eli Lilly announced on Wednesday. In topline data from the open-label phase IIIb SURMOUNT-5 trial, people on tirzepatide lost 20.2% of their body weight compared with 13.7% with semaglutide after […]
Author : News Health
Publish date : 2024-12-04 21:39:06
Copyright for syndicated content belongs to the linked Source.